Buy or sell Samumed stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Samumed Stock

R&D for tissue-level regeneration

Founded

2008

Headquarters

San Diego CA, US

Total Funding

$438M

About Samumed Stock

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Founded in San Diego, California in 2008, Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.

Funding History

August 2018$438M

Management

CEO & Founder

Osman Kibar

Chief Medical Officer

Yusuf Yazici

Chief Financial Officer

Cevdet Samikoglu

Chief Legal Officer

Arman Oruc

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Samumed or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo